Cornelius A Thiels1,2, John R Bergquist1,2, Adam C Krajewski1, Hee Eun Lee3, Heidi Nelson4, Kellie L Mathis4, Elizabeth B Habermann2, Robert R Cima5. 1. Department of Surgery, Mayo Clinic, Rochester, MN, USA. 2. Robert D. and Patricia E. Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, MN, USA. 3. Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 4. Division of Colon and Rectal Surgery, Department of Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA. 5. Division of Colon and Rectal Surgery, Department of Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA. Cima.Robert@mayo.edu.
Abstract
INTRODUCTION: Primary colorectal sarcomas are a rare entity with anecdotally poor outcomes. We sought to inform surgeons, oncologists, and researchers of the characteristics and outcomes of these understudied and difficult-to-manage tumors. METHODS: The National Cancer Data Base (NCDB) was queried for patients with pathologically confirmed primary sarcoma of the colon or rectum (1998-2012). Gastrointestinal stromal tumors were excluded. Unadjusted overall survival was reported using the Kaplan-Meier method. Patients with colorectal adenocarcinoma were used as a comparison cohort. RESULTS: Four hundred thirty-three patients with primary colorectal sarcoma were identified (57.5% leiomyosarcoma subtype). Median age was 63 [inter-quartile range 52, 75] years with 23.1% between the ages of 18 and 50 and 48.7% female. Majority of sarcomas were located in the colon (70.7%). When compared to 696,902 patients with adenocarcinoma, sarcoma patients were younger, had larger tumors, were more likely node negative and rectal in location, and higher grade (all p < 0.001), while sex, race, and comorbidity score were similar (all p > 0.05). Overall survival was lower at 5 years in patients with sarcoma (43.8%) than adenocarcinoma (52.3%, p < 0.001). CONCLUSION: Primary colorectal sarcomas are rare and present at a younger age and higher grade than adenocarcinoma of the colon and rectum. Survival is significantly worse compared to adenocarcinoma patients.
INTRODUCTION:Primary colorectal sarcomas are a rare entity with anecdotally poor outcomes. We sought to inform surgeons, oncologists, and researchers of the characteristics and outcomes of these understudied and difficult-to-manage tumors. METHODS: The National Cancer Data Base (NCDB) was queried for patients with pathologically confirmed primary sarcoma of the colon or rectum (1998-2012). Gastrointestinal stromal tumors were excluded. Unadjusted overall survival was reported using the Kaplan-Meier method. Patients with colorectal adenocarcinoma were used as a comparison cohort. RESULTS: Four hundred thirty-three patients with primary colorectal sarcoma were identified (57.5% leiomyosarcoma subtype). Median age was 63 [inter-quartile range 52, 75] years with 23.1% between the ages of 18 and 50 and 48.7% female. Majority of sarcomas were located in the colon (70.7%). When compared to 696,902 patients with adenocarcinoma, sarcomapatients were younger, had larger tumors, were more likely node negative and rectal in location, and higher grade (all p < 0.001), while sex, race, and comorbidity score were similar (all p > 0.05). Overall survival was lower at 5 years in patients with sarcoma (43.8%) than adenocarcinoma (52.3%, p < 0.001). CONCLUSION:Primary colorectal sarcomas are rare and present at a younger age and higher grade than adenocarcinoma of the colon and rectum. Survival is significantly worse compared to adenocarcinomapatients.
Entities:
Keywords:
Colorectal cancer; Leiomyosarcoma; National Cancer Database; Sarcoma
Authors: Heather G Lyu; Leah A Stein; Lily V Saadat; Sheila N Phicil; Adil Haider; Chandrajit P Raut Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: David D B Bates; Maria Clara Fernandes de Paula; Natally Horvat; Shannon Sheedy; Chandana Lall; Zahra Kassam; Perry Pickhardt; Neeraj Lalwani; Dhakshinamoorthy Ganeshan; Iva Petkovska Journal: Abdom Radiol (NY) Date: 2019-11
Authors: Meng Liu; Jigisha P Thakkar; Catherine R Garcia; Therese A Dolecek; Lars M Wagner; Emily Van Meter Dressler; John L Villano Journal: Cancer Med Date: 2018-03-13 Impact factor: 4.452
Authors: Andrew X Li; Benjamin J Resio; Maureen E Canavan; Marianna Papageorge; Daniel J Boffa; Justin D Blasberg Journal: J Thorac Dis Date: 2021-06 Impact factor: 2.895